Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

McCluggage, W. Glenn; Judge, Meagan; Clarke, Blaise A.; Davidson, Ben; Gilks, C. Blake; Hollema, Harry; Ledermann, Jonathan A.; Matías‐Guiu, Xavier; Mikami, Yoshiki; Stewart, Colin J.R.; Vang, Russell; Hirschowitz, Lynn

doi:10.1038/modpathol.2015.77

Cited by 180 publications

(157 citation statements)

References 162 publications

(201 reference statements)

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…20 Thus, it is recommended by the International Collaboration on Cancer Reporting (ICCR) that percentages of the epithelial and mesenchymal components as well the morphological subtypes within the epithelial and mesenchymal components be included on the pathology report. 21 …”

Section: Histogenesismentioning

confidence: 99%

A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus

McCluggage

2016

Modern Pathology

Self Cite

View full text Add to dashboard Cite

The current 2014 World Health Organization (WHO) Classification of mixed epithelial and mesenchymal tumours of the uterus includes categories of carcinosarcoma, adenosarcoma, adenofibroma, adenomyoma and atypical polypoid adenomyoma, the last two lesions being composed of an admixture of benign epithelial and mesenchymal elements with a prominent smooth muscle component. In this review, each of these categories of uterine neoplasm is covered with an emphasis on practical tips for the surgical pathologist and new developments. In particular, helpful clues in the distinction between carcinosarcoma and dedifferentiated endometrial carcinoma will be discussed. In addition, salient features to help distinguish between adenofibroma, adenosarcoma, embryonal rhabdomyosarcoma and other mesenchymal neoplasms in the differential diagnosis will be outlined. Finally, a discussion of adenomyoma and its main differential diagnostic considerations will be covered.

show abstract

Section: Histogenesismentioning

confidence: 99%

A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus

McCluggage

2016

Modern Pathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…141 Most clear cell carcinomas are negative for WT1 and estrogen receptors. 141 Because patients are typically diagnosed with clear cell carcinoma after pathologic analysis of a surgical specimen, the workup for suspicious or palpable pelvic masses is performed before surgery, as described in the algorithm (see OV-1; page 1136).…”

Section: Clear Cell Carcinomamentioning

confidence: 99%

“…145 Postoperative observation and monitoring are recommended for patients with stage IA or IB mucinous tumors, because most of these tumors are benign or borderline. 80,141 Fertility-sparing surgery is an option for patients with a unilateral mucinous borderline tumor (see LCOH-6; page 1141). For patients with stage IC mucinous carcinomas, postoperative options include (1) observation; (2) intravenous carboplatin with either paclitaxel or docetaxel; (3) 5-FU/leucovorin/oxaliplatin (gastrointestinal regimen); or (4) capecitabine/oxaliplatin (gastrointestinal regimen).…”

Section: Mucinous Carcinomasmentioning

confidence: 99%

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Morgan

Armstrong

Alvarez

et al. 2016

J Natl Compr Canc Netw

285

218

View full text Add to dashboard Cite

“…A uniform approach to site assignment in HGSC is recommended by the International Collaboration on Cancer Reporting (ICCR) (10), which has incorporated most of the criteria listed above in their dataset on ovarian, tubal and primary peritoneal cancer. Using an earlier modification of the criteria listed above, in 53 prospectively studied chemo-naive cases of HGSC with unknown genetic status, 83% were classified as tubal, 17% as ovarian and none as peritoneal primaries (3).…”

Section: Consensus Statementmentioning

confidence: 99%

Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide

Singh

Gilks

Hirschowitz

et al. 2016

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecologic Oncology, 141(2), pp. 195-198. There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.http://eprints.gla.ac.uk/119715/ BackgroundStrategies to improve outcomes in cancer patients are underpinned by accurate recording of high quality data in a standard format. 'Ovarian' cancer, of which by far the most common subtype is high-grade serous carcinoma (HGSC), constitutes the second commonest gynecologic malignancy and overwhelmingly the one with the highest mortality. Despite some advances in prevention, early detection, surgery and chemotherapy, the mortality rate has not decreased significantly. This makes accurate and uniform data recording essential for monitoring the impact of new strategies, both in clinical practice and trial settings.

show abstract

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Cited by 180 publications

References 162 publications

A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus

A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide

Contact Info

Product

Resources

About